All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CoronaVac
Therapeutic Area: Infections and Infectious Diseases Product Name: CoronaVac
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 23, 2020
Details:
Inactivated COVID-19 vaccine candidate "CoronaVac” is now approved by the National Medical Products Administration (NMPA) for clinical trial in adolescents and children. Vaccine to be tested in adolescents and children between the ages of 3-17 years old.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BBIBP-CorV
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2020
Details:
The vaccine candidate, dubbed BBIBP-CorV and made from an inactivated form of the virus, induced high levels of neutralizing antibodies against SARS-CoV-2—the virus behind COVID-19—in rodents, rabbits and monkeys without triggering any serious adverse event.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TJM2
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 28, 2020
Details:
Data monitoring committee (DMC) reviewed the clinical data and unanimously recommended proceeding to part 2 of the study and endorsed the change of low dose treatment arm (3mg/kg) to high dose (6mg/kg).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PiCoVacc
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 24, 2020
Details:
Study will evaluate the safety, tolerance, and preliminary immunogenicity of the Sinovac's SARS-CoV-2 vaccine by vaccinating 144 healthy adults, with two different dosages of the vaccine candidate.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Inactivated SARS-CoV-2 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2020
Details:
This study is to evaluate the safety, tolerance, and preliminary immunogenicity of the Company’s SARS-CoV-2 vaccine by vaccinating healthy adults, with two different dosages of the vaccine candidate.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TJM2
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2020
Details:
I-Mab got by the U.S.FDA to conduct a Phase I clinical trial to assess its investigational product TJM2 to treat cytokine release syndrome associated with severe illness caused by COVID-19.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
